TY - JOUR T1 - 哮喘治疗的目标：我们应该多高？JF - 欧洲呼吸杂志JO - EUR呼吸杂志SP - 715 LP - 717 DO - 10.1183 / 09031936.04.10104904 VL - 24 - 5 AU - Reddel，H.K.Y1 - 2004年11月1日UR - //www.qdcxjkg.com/content/24/5/715.abstract N2 - H.K.Reddel是由新南威尔士的哮喘基金会安J. Woolcock奖学金支持。在教科书“呼吸系统疾病”，发表于1981年，克罗夫顿和道格拉斯1开始与评论哮喘管理的讨论，“必须承认，哮喘的治疗主要是治标不治本”。本章提供死亡率高，常见的症状和治疗的致残副作用的惨淡景象。使用吸入皮质类固醇（ICS）和，的后，长效β2激动剂，已经产生了在哮喘结果非凡的改进，特别是在疾病的患者的负担。More recent attention has focussed on fine-tuning asthma treatment, the aim being to return the patient towards the disease-free state, i.e. not just to improve lung function, which has long been the preferred outcome variable for clinical trials, but to improve the whole spectrum of asthma features, summarised in the expression “asthma control”. These concepts have been addressed by Bateman et al. 2, reporting the results of the Gaining Optimal Asthma controL (GOAL) study. The GOAL study 2 arose from scientific and clinical interest in determining the proportion of asthma patients who could achieve a stringent definition of asthma control. The commercial setting within which this question was examined was a double-blind randomised controlled trial comparing salmeterol and fluticasone combination (SFC) and fluticasone propionate (FP), given b.i.d by Diskus/Accuhaler for 12 months in patients with suboptimally controlled asthma at entry. The GOAL study 2 has raised several interesting issues relating to optimal asthma management, and the way in which response to treatment should be assessed. The GOAL study 2 was planned in the late 1990s, when there was considerable interest in the potential impact of high doses of ICS, with or without long-acting β2-agonists, in achieving better outcomes in asthma. At the time, international asthma … ER -